Skip to main content
. 2026 Mar 13;26(2):10. doi: 10.1038/s41397-026-00402-8

Table 1.

Study 3201 (Bipolar Mania) Least Squares Mean Change from Baseline for Serum Urate for Iloperidone vs Placebo Treatment Groups (μmol/L).

Visit Iloperidone Placebo LS Mean Difference p-value
LS Mean Change (SE), n LS Mean Change (SE), n (95% CI)
Baseline 323.0 (77.13), 206 328.5 (84.6), 208 - -
Day 7 −2.7 (−4.07), 199 −4.0 (−4.11), 196 1.3 (−9.29, 11.88) =0.8098
Day 14 12.6 (−4.28), 173 −2.7 (−4.24), 186 15.3 (4.50, 26.15) =0.0057
Day 21 19.1 (−5.24), 157 −1.9 (−5.07), 166 21.0 (8.91, 33.18) =0.0007
Day 28 27.2 (−4.93), 142 0.1 (−4.77), 154 27.1 (14.94, 39.20) <0.0001

Baseline shown as mean (SD). LS mean change shown for each evaluation for serum urate in Study 3201 (Bipolar Mania). ANCOVA = Analysis of Covariance. CI = Confidence Interval. LS = Least Squares. SE=Standard Error. SD=Standard Deviation. Baseline is defined as the latest non-missing observation across all the visits in the Screening Phase before the first dose of study medication. LS means, CIs, and p-values are based on ANCOVA model with main effects of treatment group and pooled site, and baseline as a covariate. All p values represent the difference between iloperidone and placebo.